Sloning and BioMérieux Team to Find Gene Variants for Dx Development
 
Sloning Biotechnology and BioMérieux will collaborate on a feasibility study to develop gene variants for an enzyme BioMérieux can use in its in vitro diagnostics development programs, Sloning said this week.
 
Sloning, based in Munich, Germany, said it will use its Slonomics gene-synthesis technology to offer BioMérieux “a gene library with a full set of ratio-controlled mutants.”
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.